Promising 'first' in Alzheimer's drug development | ScienceDaily
WEB2 days ago · The drug, a peptide inhibitor called RI-AG03, was effective at preventing the build-up of Tau proteins in both lab and fruit fly studies. Skip to main content Your source for the latest research news
Alzheimer’s breakthrough after drug treatment success
WEB3 days ago · News Science Alzheimer’s breakthrough after drug treatment success Study found that the medication, called RI-AG03, was effective at preventing the buildup of Tau proteins
Alzheimer’s Game Changer: Dual-Action Drug Attacks
WEB3 days ago · A new peptide inhibitor, RI-AG03, targets two key areas of the Tau protein in Alzheimer's disease, showing effectiveness in lab and fruit fly models. This innovative approach could lead to treatments that slow disease progression with minimal side effects. An international team of scientists led
Alzheimer's 'First' Achieved With Drug That Hits Hotspots
WEB1 day ago · The compound, called RI-AG03, is a novel peptide inhibitor—a short chain of amino acids designed to block the activity of specific proteins. ... Breaking News (As it Breaks) The Debate (Twice a ...
Promising ‘first’ in Alzheimer’s drug development
WEB2 days ago · “RI-AG03 is specifically designed against the Tau protein, meaning it’s less likely to undesirably interact with other proteins.” The paper describes how RI-AG03 was first developed by Dr Aggidis, in the laboratory of the late Prof David Allsop, using computational biology at Lancaster University, where it was tested in lab dishes.
WEBThe drug, a peptide inhibitor called RI-AG03, was effective at preventing the buildup of tau proteins in both lab and fruit fly studies. The research, published in Alzheimer's & Dementia, was led ...
A novel peptide‐based tau aggregation inhibitor as a potential ...
WEB3 days ago · RI-AG03 potently suppresses aggregation of both these recombinant Tau species in a dose-dependent manner, with comparable efficacy as evidenced by similar doses of RI-AG03 required to inhibit aggregation by 50% (IC 50 for Tau Δ1-250 = 7.83 µM Figure 3C/D; IC 50 for Tau 2N4R = 5 µM Figure 3E/F).
Promising ‘first’ in Alzheimer’s drug development
WEB3 days ago · “RI-AG03 is specifically designed against the Tau protein, meaning it’s less likely to undesirably interact with other proteins.” Testing RI-AG03 The paper describes how RI-AG03 was first developed by Dr Aggidis, in the laboratory of the late Prof David Allsop, using computational biology at Lancaster University, where it was tested in ...
A novel peptide-based tau aggregation inhibitor as a potential ...
WEBRI-AG03 also rescues a biosensor cell line that stably expresses Tau repeat domains with the P301S mutation fused to Cer/Clo and rescues aggregation-dependent phenotypes in vivo, suppressing neurodegeneration and extending lifespan. Collectively our data describe several properties and attributes of RI-AG03 that make it a promising disease ...
Promising ‘first’ in Alzheimer’s drug development
WEB3 days ago · Testing RI-AG03. To test its effectiveness in cells within a living organism, researchers at the University of Southampton then gave the drug to fruit flies that had pathogenic Tau. ... Back to News. Our research represents an important step toward creating treatments that can prevent the progression of diseases like …
- Some results have been removed